Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. News
  7. Summary
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
Delayed Japan Exchange  -  01:00:00 2023-01-27 am EST
8149.00 JPY   -1.59%
08:00aDisappointing Tech Earnings, Outlook Weigh on Exchange-Traded Funds, Equity Futures Pre-Bell
MT
05:33aBiogen, Eisai Say European Medicines Agency Accepts for Review Regulatory Application for Alzheimer's Disease Drug
MT
01/26Eisai : Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies

11/29/2022 | 05:37am EST

TOKYO, Nov 29, 2022 - (JCN Newswire) - - Eisai Co., Ltd. announced that its application for a partial change to label for Aricept (donepezil hydrochloride), a treatment for Alzheimer's disease and dementia with Lewy bodies (DLB) that was discovered and developed in-house, regarding dosage and administration for the treatment of DLB in Japan, has been approved today. (Please refer to "Notes to Editors" on the link below for details of the changes)

This partial change to label is based on the results of a reexamination for the indication of "suppression of progression of dementia symptoms in dementia with Lewy bodies" of this drug, which was categorized as Category 2.

After receiving approval for the partial change in dosage and administration for DLB, Eisai will continue to place the highest priority on the provision of proper use and safety information for this drug, and will make continued contributions to address the diversified needs of, and increase the benefits provided to people living with DLB and their families.

For more information visit www.eisai.com/news/2022/news202282.html.

Media Inquiries:

Public Relations Department,

Eisai Co., Ltd.

+81-(0)3-3817-5120

Copyright 2022 JCN Newswire . All rights reserved.

© Japan Corporate News, source JCN Press Releases

All news about EISAI CO., LTD.
08:00aDisappointing Tech Earnings, Outlook Weigh on Exchange-Traded Funds, Equity Futures Pre..
MT
05:33aBiogen, Eisai Say European Medicines Agency Accepts for Review Regulatory Application f..
MT
01/26Eisai : Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer..
AQ
01/26BioArctic, Eisai's Regulatory Application for Alzheimer's Disease Drug Accepted in EU
MT
01/26Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization
DJ
01/26European Medicines Agency accepts Marketing Authorization Application for lecanemab as ..
AQ
01/26Eisai Accepts Marketing Authorization Application for Lecanemab as Treatment for Early ..
CI
01/26Eisai Co., Ltd. and Biogen Inc. Announce European Medicines Agency Accepts Marketing Au..
CI
01/25Lonza underscores growth prospects with share buy-back, dividend hike
RE
01/23Sinking Yen, Wall Street Cues Drive Tokyo Shares Higher
MT
More news
Financials
Sales 2023 744 B 5 730 M 5 730 M
Net income 2023 57 359 M 441 M 441 M
Net cash 2023 209 B 1 609 M 1 609 M
P/E ratio 2023 41,3x
Yield 2023 1,97%
Capitalization 2 338 B 17 996 M 17 996 M
EV / Sales 2023 2,86x
EV / Sales 2024 2,72x
Nbr of Employees 11 322
Free-Float 93,3%
Chart EISAI CO., LTD.
Duration : Period :
Eisai Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 8 149,00 JPY
Average target price 9 175,00 JPY
Spread / Average Target 12,6%
EPS Revisions
Managers and Directors
Haruo Naito Manager-Research & Development Promotions
Tatsuyuki Yasuno Manager-Corporate Planning
Yasuhiko Katoh Chairman
Keisuke Naito Executive Officer & Head-Global IT Headquarters
Yasushi Okada Manager-Business Planning
Sector and Competitors
1st jan.Capi. (M$)
EISAI CO., LTD.-4.86%18 219
JOHNSON & JOHNSON-4.04%441 560
ELI LILLY AND COMPANY-4.40%330 671
NOVO NORDISK A/S0.14%309 711
ROCHE HOLDING AG-0.52%277 411
MERCK & CO., INC.-3.68%270 958